RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Zebra-Med

Company

Pharmaceuticals, medicine, healthcare
Since 2014
Middle East
Shefayim, HaMerkaz, Israel


An analytical company offering solutions in the field of medicine based on artificial intelligence technologies

Owners:
Nano-X Imaging

Content

Owners

History

2021: Nano-X Imaging bought Zebra Medical Vision for $200 million

On August 10, 2021, the sale of Zebra Medical Vision to Nano-X Imaging, which develops computer vision technologies in the health sector, was announced. The transaction amount will be about $200 million: the buyer will pay $100 million in advance and another $100 million in shares.

Computer vision, which is associated with algorithms that allow for a high-level understanding of images and videos, is used in various fields of medicine. Although some studies raise concerns about bias, startups and operating companies are hunting for a market that is projected by Verified Market Research to be $5.31 billion in volume by 2026.

Nano-X Imaging acquired Zebra Medical Vision for $200 million

In anticipation of the acquisition, Zebra shifted from diagnostics and sorting to using its data to help health systems assess a large number of patients for chronic diseases. If the acquisition is completed, CEO Zohar Elhanani says Zebra will combine its capabilities with the acquiring company's strategy to accelerate the development of the population healthcare concept and make medical imaging more effective by 2024.

File:Aquote1.png
Zebra Medical Vision has always worked to expand the use of artificial intelligence in medical imaging to improve the health of patients worldwide, said Zohar Elhanani, CEO of Zebra Medical Vision.
File:Aquote2.png

Zohar Elhanani added that as of August 2021, they have a common understanding that in order to achieve this goal, it is best to join forces with a reliable partner with the means to expand our capabilities and bring population-based AI-based health care to a new level. Screening the population for early detection and treatment of chronic diseases has proven improved outcomes, and we are pleased to be at the helm of public health transformations in healthcare.[1]

Notes